The global single-use bioprocessing market is expected to grow from USD 30.12 billion in 2025 to USD 122.92 billion by 2035 at a CAGR of 15.1%. Driven by technological breakthroughs in bioreactor scalability (up to 6,000L), 40-50% CAPEX reductions, and FDA approvals of 16 single-use-manufactured biologics in 2024, the market is becoming the standard for commercial biomanufacturing. Major players are expanding capacity significantly, with CDMOs like WuXi Biologics managing substantial backlogs.
Repligen Corp (RGEN)
Common Stock · Currency in USD · XNAS
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
Company Info
SIC2836
Composite FIGIBBG000BS48J3
CIK0000730272
IPOApr 29, 1986
Sectorbiological products, (no diagnostic substances)
Highlights
Market Cap$6.63B
EPS$1.08
P/E Ratio111.24
Revenue$742.34M
Gross Profit$402.06M
Net Income$59.64M
Employees2,000
WSO56,331,110
Phone(781) 449-9560
Websitehttps://www.repligen.com
Related Tickers
Analysis
Share Price Chart
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Repligen Corp, comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Returns By Period
Repligen Corp (RGEN) has returned -27.98% so far this year and 11.34% over the past 12 months. Looking at the last ten years, RGEN has achieved an annualized return of 15.76%, outperforming the Benchmark (SPY), which averaged 12.23% per year.
RGEN
1M-5.02%
6M-20.04%
YTD-27.98%
1Y11.34%
5Y-10.52%
10Y15.76%
Benchmark (SPY)
1M-3.85%
6M-2.35%
YTD-4.36%
1Y34.06%
5Y9.80%
10Y12.23%
Monthly Returns
The table below presents the monthly returns of Repligen Corp (RGEN) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -8.66% | -13.77% | -6.69% | -0.64% | ||||||||
| 2025 | 14.34% | -2.11% | -20.20% | 7.99% | -15.51% | 5.40% | -5.60% | 6.15% | 10.08% | 10.67% | 15.93% | -2.79% |
| 2024 | 7.13% | 1.80% | -4.30% | -11.23% | -6.23% | -16.30% | 32.88% | -10.44% | -0.17% | -10.01% | 12.12% | -4.09% |
| 2023 | 8.22% | -6.24% | -3.06% | -9.14% | 10.78% | -15.49% | 21.31% | 2.84% | -9.46% | -14.88% | 18.30% | 15.25% |
| 2022 | -25.37% | -1.92% | -4.54% | -15.77% | 6.72% | -1.71% | 31.55% | 3.00% | -13.68% | -2.98% | 6.45% | -5.72% |
| 2021 | 3.83% | 5.40% | -10.19% | 7.25% | -13.77% | 9.31% | 23.28% | 14.74% | 2.81% | 0.70% | -1.40% | -7.59% |
| 2020 | 7.88% | -15.85% | 11.68% | 23.46% | 14.35% | -5.27% | 21.30% | 1.61% | -5.16% | 12.55% | 10.69% | 0.33% |
| 2019 | 8.94% | 4.33% | -1.42% | 12.58% | 10.18% | 23.76% | 8.32% | -2.65% | -17.13% | 3.83% | 8.24% | 4.12% |
| 2018 | -2.72% | -2.34% | 5.64% | 2.69% | 18.25% | 7.67% | 3.11% | 13.53% | 1.41% | -2.66% | 15.71% | -19.95% |
| 2017 | -2.47% | 4.55% | 9.79% | 4.46% | 6.66% | 4.88% | -2.73% | 8.17% | -12.73% | -7.12% | -5.72% | 2.25% |
| 2016 | 0.08% | -10.06% | 14.29% | 4.30% | 8.39% | -2.74% | -4.77% | 12.67% | -4.64% |
Performance Indicators
The charts below present risk-adjusted performance metrics for Repligen Corp (RGEN) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
Sharpe ratio
Sortino ratio
Omega ratio
Calmar ratio
Martin ratio
sharpe ratio
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of RGEN compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
Volatility Chart
The current Repligen Corp volatility is 3.00%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
Income Statement
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 2.95B | 2.83B | 2.82B | 2.52B | 2.36B | 1.90B | 1.40B | 774.62M | 743.52M | 288.91M | 146.24M | 128.29M | 118.64M | 97.01M | 76.06M |
| Equity Attributable To Parent (USD) | 2.11B | 1.97B | 1.97B | 1.91B | 1.75B | 1.53B | 1.06B | 615.57M | 591.55M | 168.76M | 122.75M | 111.73M | 103.89M | 84.12M | 65.99M |
| Equity Attributable To Noncontrolling Interest (USD) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Equity (USD) | 2.11B | 1.97B | 1.97B | 1.91B | 1.75B | 1.53B | 1.06B | 615.57M | 591.55M | 168.76M | 122.75M | 111.73M | 103.89M | 84.12M | 65.99M |
| Other Non-current Liabilities (USD) | 165.53M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Long-term Debt (USD) | 542.21M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Noncurrent Liabilities (USD) | 707.74M | 730.16M | 695.05M | 209.76M | 233.03M | 54.78M | 292.03M | 29.21M | 126.76M | 99.07M | 4.71M | 5.88M | 3.46M | 2.13M | 2.61M |
| Other Current Liabilities (USD) | 65.68M | 62.49M | 121.94M | 343.12M | 296.91M | 281.79M | 17.04M | 109.40M | 8.37M | 10.43M | 7.38M | 3.06M | 6.41M | 4.66M | 6.04M |
| Wages (USD) | 40.14M | 32.16M | 16.66M | 33.52M | 42.15M | 20.29M | 19.85M | 9.95M | 9.56M | 5.59M | 4.68M | 3.76M | 3.17M | 3.63M | - |
| Accounts Payable (USD) | 30.01M | 32.13M | 19.56M | 27.55M | 36.20M | 16.88M | 11.43M | 10.49M | 7.28M | 5.06M | 6.72M | 3.86M | 1.72M | 2.45M | 1.42M |
| Current Liabilities (USD) | 135.83M | 126.79M | 158.16M | 404.20M | 375.26M | 318.96M | 48.31M | 129.84M | 25.21M | 21.08M | 18.78M | 10.68M | 11.30M | 10.75M | 7.46M |
| Liabilities (USD) | 843.57M | 856.95M | 853.21M | 613.96M | 608.29M | 373.74M | 340.35M | 159.05M | 151.97M | 120.15M | 23.49M | 16.56M | 14.76M | 12.89M | 10.07M |
| Other Non-current Assets (USD) | 1.24B | 1.17B | 1.11B | 982.19M | 964.44M | 646.54M | 497.28M | 331.26M | 333.57M | 60.00M | 16.43M | 18.19M | 13.60M | 13.67M | 10.63M |
| Intangible Assets (USD) | 386.15M | 397.90M | 400.49M | 353.68M | 337.27M | 287.10M | 212.55M | 135.44M | 144.75M | 29.81M | 12.76M | 14.64M | 6.19M | 7.18M | 7.80M |
| Fixed Assets (USD) | 186.61M | 197.74M | 207.44M | 190.67M | 124.96M | 66.87M | 48.46M | 32.18M | 22.42M | 14.96M | 13.80M | 14.53M | 12.51M | 9.95M | 10.74M |
| Noncurrent Assets (USD) | 1.81B | 1.76B | 1.71B | 1.53B | 1.43B | 1.00B | 758.29M | 498.88M | 500.74M | 104.76M | 42.99M | 47.35M | 32.29M | 30.80M | 29.16M |
| Other Current Assets (USD) | 966.93M | 923.08M | 908.72M | 759.84M | 747.18M | 807.36M | 587.00M | 233.48M | 203.78M | 159.46M | 85.25M | 68.56M | 74.55M | 55.07M | 33.53M |
| Inventory (USD) | 170.46M | 142.96M | 202.32M | 238.28M | 184.49M | 95.03M | 54.83M | 42.26M | 39.00M | 24.70M | 18.00M | 12.38M | 11.80M | 11.14M | 13.36M |
| Current Assets (USD) | 1.14B | 1.07B | 1.11B | 998.12M | 931.68M | 902.38M | 641.83M | 275.74M | 242.78M | 184.15M | 103.25M | 80.95M | 86.35M | 66.21M | 46.89M |
| Assets (USD) | 2.95B | 2.83B | 2.82B | 2.52B | 2.36B | 1.90B | 1.40B | 774.62M | 743.52M | 288.91M | 146.24M | 128.29M | 118.64M | 97.01M | 76.06M |
News and Insights
The global continuous bioprocessing market is projected to grow from USD 319.77 million in 2025 to USD 2,331.98 million by 2035 at a CAGR of 21.98%. Driven by demand for biosimilars and complex biologics, manufacturers are shifting from traditional fed-batch to continuous methods, achieving 50% cost reductions and significant sustainability improvements. North America leads with 39% market share, while Asia Pacific rapidly expands capacity. Major pharmaceutical and biotech companies are deploying billions in capital investments to modernize manufacturing infrastructure.
The filtration in biologics market is projected to experience significant growth from 2024 to 2034, driven by increasing demand for monoclonal antibodies, vaccines, and cell and gene therapies, with North America leading and Asia Pacific showing the fastest growth potential.
Repligen, a bioprocessing technology company, reported mixed Q4 results. While adjusted EPS exceeded expectations, GAAP gross margin declined significantly due to restructuring and other costs. The company is focused on product innovations and strategic acquisitions to drive growth.
Chromatography System Market to Reach US$ 2.62 Billion with 6.6% CAGR by 2034 | Fact.MR Reportpositive
The global chromatography system market is expected to grow at a CAGR of 6.6% from 2024 to 2034, driven by increasing applications in the biotechnology sector and technological advancements that simplify procedures and reduce human error.
BioLife Solutions, a leading developer and supplier of bioproduction tools and services for the cell and gene therapy market, has appointed Tony J. Hunt, Executive Chairman of Repligen Corporation, to its board of directors. Hunt's appointment is expected to strengthen BioLife's focus on extending its position as a provider of industry-leading solutions for bioproduction workflows in the cell and gene therapy market.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Deutsche Bank analyst Justin Bowers upgraded the rating for Repligen Corporation (NASDAQ:RGEN) from Hold to Buy, but lowered the price target from $180 to $155. Repligen shares fell 0.4% to close at $123.15 on Tuesday. See how other analysts view this stock. Wolfe Research analyst Steven Chubak upgraded Robinhood Markets, Inc. (NASDAQ:HOOD) from Peer Perform to Outperform, while announcing a price target of $29. Robinhood shares gained 3.6% ...Full story available on Benzinga.com
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Citigroup raised the price target for NVIDIA Corporation (NASDAQ:NVDA) from $126 to $150. Citigroup analyst Atif Malik maintained a Buy rating. NVIDIA shares gained 6.8% to close at $126.09 on Tuesday. See how other analysts view this stock. Truist Securities raised the price target for Rivian Automotive, Inc. (NASDAQ:RIVN) from $10 to $13. Truist Securities analyst Jordan Levy maintained a Hold rating. Rivian Automotive shares gained 8.6% to close at $11.96 on Tuesday. See how other analysts view this stock. BTIG cut Exact Sciences Corporation (NASDAQ:EXAS) price target from $80 to $70. BTIG analyst Mark Massaro maintained a Buy rating. Exact Sciences shares fell 1.4% to close at $41.37 on Tuesday. See how other analysts view this stock. Morgan Stanley boosted the price target for FedEx Corporation (NYSE:Full story available on Benzinga.com
Repligen (RGEN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Repligen (RGEN) appoints Olivier Loeillot as the company's new president and chief executive officer, effective from Sep 1, 2024. Stock falls on the news.